OBJECTIVE: To investigate the possibility of drug-free remission in patients with psoriatic arthritis (PsA) in continuous remission. METHODS: Prospective observational study in disease-modifying antirheumatic drug (DMARD)-treated PsA patients in continuous disease remission (no musculoskeletal symptoms, no or minimal skin/nail disease) for at least 6 months. Demographic, disease-specific and ultrasound parameters were assessed at baseline. DMARDs (traditional or biologic) were discontinued at the initial visit, and patients were followed for a maximum of 6 months for recurrence of disease. RESULTS: 26 patients (methotrexate monotherapy: N=14; tumour necrosis factor inhibitors: N=12) with a mean age of 55.2 years, absence of musculoskeletal symptoms and minimal skin disease (mean Psoriasis Area Severity Index (PASI): 0.21) were enrolled. Incidence of recurrence of disease was high (N=20, 76.9%) and occurred rapidly (74.50±51.72 days) after treatment discontinuation. Male PsA patients were significantly more likely to lose remission. Long disease duration, more severe skin involvement and the presence of synovial hypertrophy by ultrasonographic examination at baseline decreased the likelihood for drug-free remission. Reinitiation of DMARDs promptly restored remission in all PsA patients with recurrence of disease. CONCLUSIONS: This study shows that the chance to reach drug-free remission in PsA patients is low. Discontinuation of DMARD therapy cannot be recommended in patients with PsA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: To investigate the possibility of drug-free remission in patients with psoriatic arthritis (PsA) in continuous remission. METHODS: Prospective observational study in disease-modifying antirheumatic drug (DMARD)-treated PsA patients in continuous disease remission (no musculoskeletal symptoms, no or minimal skin/nail disease) for at least 6 months. Demographic, disease-specific and ultrasound parameters were assessed at baseline. DMARDs (traditional or biologic) were discontinued at the initial visit, and patients were followed for a maximum of 6 months for recurrence of disease. RESULTS: 26 patients (methotrexate monotherapy: N=14; tumour necrosis factor inhibitors: N=12) with a mean age of 55.2 years, absence of musculoskeletal symptoms and minimal skin disease (mean Psoriasis Area Severity Index (PASI): 0.21) were enrolled. Incidence of recurrence of disease was high (N=20, 76.9%) and occurred rapidly (74.50±51.72 days) after treatment discontinuation. Male PsA patients were significantly more likely to lose remission. Long disease duration, more severe skin involvement and the presence of synovial hypertrophy by ultrasonographic examination at baseline decreased the likelihood for drug-free remission. Reinitiation of DMARDs promptly restored remission in all PsA patients with recurrence of disease. CONCLUSIONS: This study shows that the chance to reach drug-free remission in PsA patients is low. Discontinuation of DMARD therapy cannot be recommended in patients with PsA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Seemal R Desai; Ilona J Frieden; Joel M Gelfand; Whitney High; Arthur Kavanaugh; Ashfaq A Marghoob; David M Ozog; Ted Rosen; Linda Stein Gold; Bruce Strober; Neil Swanson; George Martin Journal: J Clin Aesthet Dermatol Date: 2015-09
Authors: Iustina Janta; Lina Martínez-Estupiñán; Lara Valor; María Montoro; Ofelia Baniandres Rodriguez; Ignacio Hernández Aragüés; Natalia Bello; Diana Hernández-Flórez; Michelle Hinojosa; Julia Martínez-Barrio; Juan Carlos Nieto-González; Juan Gabriel Ovalles-Bonilla; Carlos Manuel González; Francisco Javier López-Longo; Indalecio Monteagudo; Esperanza Naredo; Luis Carreño Journal: Clin Rheumatol Date: 2015-01-31 Impact factor: 2.980
Authors: Celia A J Michielsens; Nathan den Broeder; Michelle L M Mulder; Frank H J van den Hoogen; Lise M Verhoef; Alfons A den Broeder Journal: Rheumatology (Oxford) Date: 2022-05-30 Impact factor: 7.046
Authors: Claire Rothery; Laura Bojke; Gerry Richardson; Chris Bojke; Anna Moverley; Laura Coates; Liz Thorp; Robin Waxman; Philip Helliwell Journal: Clin Rheumatol Date: 2016-10-31 Impact factor: 2.980
Authors: Stefano Alivernini; Barbara Tolusso; Luca Petricca; Laura Bui; Gabriele Di Sante; Giusy Peluso; Roberta Benvenuto; Anna Laura Fedele; Franco Federico; Gianfranco Ferraccioli; Elisa Gremese Journal: Ann Rheum Dis Date: 2017-01-24 Impact factor: 19.103
Authors: Luisa Costa; Carlo Perricone; Maria Sole Chimenti; Antonio Del Puente; Paolo Caso; Rosario Peluso; Paolo Bottiglieri; Raffaele Scarpa; Francesco Caso Journal: Drugs R D Date: 2017-12